By SaiyanMed Research Team · Updated 5 November 2026 · For in-vitro research use only
RESEARCH USE ONLY — PROFESSIONAL LABORATORY USE. This article is for qualified laboratory personnel carrying out in-vitro assays or institutionally approved laboratory animal studies. It is not a home-use, personal-use, human-use, or veterinary-use guide. The information below must not be used as an administration, formulation, reconstitution, or dosing plan. Retatrutide (LY3437943) is an investigational compound. Its safety and efficacy have not been approved for marketing by the FDA or other regulators for any indication. Clinical trial results are summarized here as published research data, not as medical advice. Eli Lilly states that retatrutide cannot be legally sold or marketed for human use [Lilly TRANSCEND IR 2026-10-28].
Quick answer
Retatrutide (development code LY3437943; sometimes shortened to “Reta” in research communities) is an investigational unimolecular triple hormone receptor agonist developed by Eli Lilly and Company. Sponsor materials describe a single peptide that activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon, studied as a once-weekly subcutaneous investigational product in Phase 3 obesity, type 2 diabetes, and related cardiometabolic programs [Lilly TRIUMPH-2 detailed 2026-09-29; Lilly TRANSCEND IR 2026-10-28].
Major Phase 3 umbrellas include TRIUMPH (obesity / overweight and complications such as type 2 diabetes, OSA, knee osteoarthritis pain) and TRANSCEND-T2D (type 2 diabetes registrational head-to-heads). Public 2026 readouts include TRIUMPH-2 (obesity + T2D; detailed at EASD 2026), TRIUMPH-3 (severe obesity + established CVD), and TRANSCEND-T2D-2 (head-to-head vs injectable semaglutide 2 mg) [Lilly 2026-07-23; Lilly 2026-09-29; Lilly 2026-10-28]. Lilly has stated plans to submit a Biologics License Application (BLA) in Q1 2027 [Lilly 2026-07-23; Lilly 2026-09-29].
Retatrutide is not the same molecule as dual GIP/GLP-1 agonists such as tirzepatide, mono GLP-1 agonists such as semaglutide, or amylin-pathway peptides such as eloralintide, petrelintide, or cagrilintide.
For laboratory reference-material context (not clinical drug product), SaiyanMed maintains a separate RUO listing: Retatrutide research reference material.
Triple agonist receptor pharmacology
What “triple agonist” means in sponsor framing
Lilly describes retatrutide as a single molecule that activates three GPCR targets central to metabolic research: GIPR, GLP-1R, and the glucagon receptor (GCGR) [Lilly 2026-09-29]. That is distinct from:
| Approach | Example (research / approved context) | Public receptor headline |
|---|---|---|
| Mono GLP-1 RA | Semaglutide | GLP-1R |
| Dual GIP/GLP-1 | Tirzepatide | GIPR + GLP-1R |
| Triple GIP/GLP-1/glucagon | Retatrutide | GIPR + GLP-1R + GCGR |
| Dual glucagon/GLP-1 | Survodutide (BI/Zealand) | GCGR + GLP-1R (no GIP headline) |
| Amylin ± incretin | Eloralintide; CagriSema; zenagamtide | Amylin pathway ± GLP-1 (different class story) |
Adding glucagon-receptor agonism is the headline differentiator versus tirzepatide-class dual agonism in pipeline narratives. Mechanistic implications for energy expenditure, hepatic lipid biology, and receptor crosstalk are discussed in SaiyanMed’s deeper MoA page: Retatrutide receptor pharmacology and structural basis of GIPR. This hub stays at the “what is” / evidence-map level and does not replace that article.
Hedges that belong in any careful research summary
- In-vitro potency rankings are assay-specific (cell background, albumin, readout). Do not invent EC50 tables here.
- Clinical % weight / A1C figures are not a reconstitution recipe or a ranking of “which vial to buy for patients.”
- Glucagon-pathway biology in animals or humans does not authorize personal or veterinary use of research powders.
How it differs from tirzepatide and semaglutide (mechanism, not “better for patients”)
Cross-trial % weight loss is not a clinical ranking. Populations, durations, estimands, background therapy, and open-label vs blinded designs differ. The table below is a mechanism / program map for researchers — not a treatment recommendation.
| Dimension | Retatrutide | Tirzepatide | Semaglutide |
|---|---|---|---|
| Public MoA headline | Unimolecular GIP / GLP-1 / glucagon RA [Lilly] | Dual GIP / GLP-1 RA (approved products exist) | Mono GLP-1 RA (approved products exist) |
| Built-in GCGR agonism? | Yes (sponsor framing) | No (as dual incretin) | No |
| Regulatory status (as of this draft) | Investigational; BLA planned Q1 2027 per Lilly [Lilly 2026-07-23] | Approved medicines in multiple indications (e.g., Mounjaro / Zepbound branding in Lilly safety summaries) | Approved medicines (e.g., Ozempic / Wegovy branding depending on indication) |
| Phase 3 H2H vs semaglutide 2 mg (T2D) | TRANSCEND-T2D-2 topline [Lilly 2026-10-28] | Separate tirzepatide vs semaglutide literature exists historically — not this page’s job | Active comparator in TRANSCEND-T2D-2 |
| Phase 3 H2H vs tirzepatide | Lilly notes TRIUMPH-5 ongoing H2H in obesity ± T2D [Lilly 2026-10-28] | Comparator in TRIUMPH-5 (ongoing; no topline cited here) | — |
RUO note: Approved dual/mono incretin medicines are not interchangeable with a research-lot retatrutide vial. Do not treat grey-market “reta” as clinical-trial drug product or as a substitute for tirzepatide/semaglutide prescriptions.
Related SaiyanMed reading: tirzepatide vs semaglutide, eloralintide vs retatrutide.
TRIUMPH Phase 3 program overview
Lilly describes the initial TRIUMPH Phase 3 clinical development program as evaluating retatrutide for obesity or overweight, type 2 diabetes, moderate-to-severe obstructive sleep apnea (OSA), and knee osteoarthritis pain across four global registrational trials, begun in 2023, with more than 5,800 participants enrolled [Lilly 2026-09-29; Lilly 2026-07-23]. Broader pipeline language also lists chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease among study themes [Lilly 2026-09-29].
TRIUMPH-2 (NCT05929079) — design snapshot
From ClinicalTrials.gov and Lilly’s About-trial sections [NCT05929079; Lilly 2026-09-29]:
| Field | Public value |
|---|---|
| Official framing | Master protocol for T2D + obesity/overweight; basket includes OSA subset (GSA2) |
| Status | Completed (CT.gov; primary completion 2026-06-16) |
| Phase | 3 |
| Enrollment | 1,152 actual |
| Randomization | 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo |
| Duration | 80 weeks treatment + 4-week post-treatment follow-up (Lilly) |
| Escalation (as described by Lilly) | Start 2 mg once weekly; step every 4 weeks to target (4 via 2; 9 via 2/4/6; 12 via 2/4/6/9) |
| Primary outcome (CT.gov) | Percent change in body weight, baseline to week 80 (+ AHI for OSA subset) |
Compliance note: Escalation schedules above are trial-protocol descriptions from the sponsor, not laboratory reconstitution or personal titration instructions. Do not copy them onto RUO vial use.
TRIUMPH-3 (NCT05882045) — design snapshot
From Lilly [Lilly 2026-07-23]:
| Field | Public value |
|---|---|
| Population | Severe obesity (Class 2 or 3; BMI ≥35 kg/m²) and established cardiovascular disease, with or without T2D |
| Enrollment | 1,949 randomized |
| Arms | Retatrutide 9 mg, 12 mg, or placebo (1:1:2) |
| Duration | 80 weeks |
| Escalation | Same stepwise 2 mg start / every-4-weeks theme as described for TRIUMPH-2 |
Other TRIUMPH-numbered studies (e.g., OSA basket within TRIUMPH-2; TRIUMPH-5 vs tirzepatide) are named in sponsor materials; cite each record individually when expanding — do not invent enrollment or toplines for unfetched IDs.
Recent public readouts
Every figure below is a trial-reported outcome under Lilly’s stated efficacy estimand (roughly: efficacy if participants remained on study intervention for 80 weeks without prohibited weight-management treatments / glycemic rescue as defined). None of it is a dosing schedule, eligibility recommendation, or product claim for research vials.
TRIUMPH-2 detailed results — 2026-09-29 (EASD Milan; Lancet simultaneous)
Adults with type 2 diabetes and obesity or overweight. Baseline averages cited by Lilly: body weight 106.4 kg (234.6 lbs); BMI 38.2; A1C 7.7% [Lilly 2026-09-29].
| Endpoint at 80 weeks (efficacy estimand) | Reta 4 mg | Reta 9 mg | Reta 12 mg | Placebo |
|---|---|---|---|---|
| Body-weight % change | −12.7% (−29.8 lbs) | −19.1% (−45.4 lbs) | −20.8% (−49.6 lbs) | −4.0% (−9.3 lbs) |
| A1C change (%-points) | −1.4 | −1.6 | −1.5 | −0.2 |
| % achieving A1C ≤6.5% | 73.1% | 79.2% | 79.0% | 26.3% |
| % achieving A1C <5.7% | 28.4% | 40.0% | 39.3% | 4.4% |
| % with ≥15% weight reduction | 36.6% | 62.2% | 67.0% | 6.4% |
| % with ≥20% weight reduction | 24.0% | 45.3% | 52.0% | 1.5% |
| % with ≥25% weight reduction | 10.8% | 30.6% | 34.9% | 0.8% |
Additional sponsor-reported notes [Lilly 2026-09-29]:
- Among participants with baseline BMI ≥35, retatrutide 12 mg lost an average of 60.8 lbs (23.4%).
- By study end, 59.5% of participants on 12 mg no longer met BMI criteria for obesity (sponsor framing).
- Highest dose: average reductions of 39.5% triglycerides, 19.6% non-HDL cholesterol, 10.8 mmHg systolic BP, 6.7 in (16.9 cm) waist circumference, 58.3% hsCRP.
- Most common AEs (4 / 9 / 12 mg vs placebo): diarrhea 27.4% / 33.5% / 33.6% vs 13.2%; nausea 13.7% / 20.8% / 28.0% vs 8.0%; constipation 14.0% / 16.2% / 16.8% vs 9.4%; decreased appetite 5.8% / 12.3% / 17.1% vs 4.5%; vomiting 5.5% / 10.2% / 15.7% vs 4.2%. Dysesthesia 4.5% / 5.6% / 7.3% vs 0.7%; UTI 3.8% / 6.3% / 8.0% vs 6.6%.
- Discontinuation due to AEs: 3.8% / 11.6% / 7.7% vs placebo 4.9%.
- OSA basket results within TRIUMPH-2 deferred to a future meeting/journal per Lilly.
Gap flag: Lilly states simultaneous Lancet publication; this draft cites the IR table, not a fetched Lancet DOI/full text.
TRIUMPH-3 topline — 2026-07-23
Severe obesity + established CVD [Lilly 2026-07-23]:
| Endpoint at 80 weeks (efficacy estimand) | Reta 9 mg | Reta 12 mg | Placebo |
|---|---|---|---|
| Body-weight % change (baseline avg 111.4 kg; BMI 40.4) | −21.6% (−52.7 lbs) | −22.6% (−55.8 lbs) | −3.2% (−7.7 lbs) |
Cardiovascular risk-factor averages at highest dose (sponsor): triglycerides −37.0%; non-HDL-C −16.5%; SBP −9.3 mmHg; waist −7.5 in (19.0 cm); hsCRP −51.2% [Lilly 2026-07-23].
MACE exploratory analyses (not a CVOT claim): pooled retatrutide 9+12 mg vs placebo — MACE-5 HR 0.82 (95% CI 0.55–1.22); MACE-3 HR 1.12 (95% CI 0.64–1.96). Lilly notes MACE occurred less frequently than anticipated in both arms; CIs include 1.0 — do not spin this as proven CV benefit [Lilly 2026-07-23].
AE pattern again GI-dominant; discontinuation due to AEs 9.8% (9 mg) / 13.5% (12 mg) vs placebo 4.8% [Lilly 2026-07-23].
TRANSCEND T2D head-to-head context
Why TRANSCEND-T2D-2 matters for literature mapping
TRANSCEND-T2D-2 is Lilly’s first Phase 3 head-to-head of retatrutide versus another incretin medicine — injectable semaglutide (Ozempic) 2 mg, described as the highest approved dose for that comparison [Lilly 2026-10-28]. It sits in a three-trial TRANSCEND-T2D program (>2,050 participants enrolled; started 2024) [Lilly 2026-10-28].
Design (registry + sponsor)
| Field | Public value |
|---|---|
| NCT | NCT06260722 |
| Design | Phase 3, randomized, multicenter, open-label |
| Population | Adults with T2D inadequately controlled on metformin ± SGLT2i; A1C 7.0–10.5%; BMI ≥25 |
| Randomization (Lilly) | 2:2:1 to retatrutide 9 mg, 12 mg, or Ozempic 2 mg; n=1,298 |
| Primary objective (Lilly) | Show retatrutide 12 mg noninferior to Ozempic 2 mg on A1C at 80 weeks |
| Status color | CT.gov: ACTIVE_NOT_RECRUITING; primary completion 2026-08-27; completion estimated 2027-02 (extension noted by Lilly ~650 continue +24 weeks) |
CT.gov lists estimated enrollment 1,250; Lilly’s topline cites 1,298 randomized — prefer the IR figure for the completed randomization count when summarizing the readout [NCT06260722; Lilly 2026-10-28].
Topline efficacy — 2026-10-28
Baseline averages (Lilly): A1C 8.3%; weight 102.4 kg (225.8 lbs); BMI 36.8 [Lilly 2026-10-28].
| Endpoint at 80 weeks (efficacy estimand) | Reta 9 mg | Reta 12 mg | Ozempic 2 mg |
|---|---|---|---|
| A1C change | −2.2% | −2.2% | −1.8% |
| Body-weight % change | −19.5% (−44.3 lbs) | −20.9% (−47.4 lbs) | −9.4% (−20.9 lbs) |
Lilly states retatrutide met primary and all key secondary endpoints, with greater A1C reduction and substantially more weight loss than Ozempic; improvements also reported on non-HDL cholesterol, triglycerides, and systolic BP [Lilly 2026-10-28]. Detailed results deferred to a future medical meeting / peer-reviewed journal.
Common AEs (9 mg / 12 mg vs Ozempic): diarrhea 28.3% / 32.7% vs 26.4%; nausea 21.2% / 23.8% vs 21.3%; constipation 14.2% / 13.1% vs 19.8%; vomiting 10.2% / 15.0% vs 13.2%; dyspepsia 10.4% / 8.5% vs 11.6%. Dysesthesia 4.8% / 6.5% vs 2.7%. AE discontinuations 4.8% / 7.9% vs 2.7% [Lilly 2026-10-28].
Open-label caveat: TRANSCEND-T2D-2 is open-label versus a marketed comparator. That design choice is useful for decision-context research questions; it is not identical to a double-blind placebo trial like TRIUMPH-2.
Lilly also flags ongoing TRIUMPH-5 head-to-head versus tirzepatide in obesity with or without T2D — no topline cited in the Oct 28 release beyond that note [Lilly 2026-10-28].
Regulatory status
| Fact | Source framing |
|---|---|
| Not FDA-approved / not marketed for human use anywhere | Lilly: investigational; “cannot be legally sold or marketed for human use”; “Anyone purporting to sell retatrutide to consumers is breaking the law” [Lilly 2026-10-28; Lilly 2026-09-29] |
| Planned U.S. filing | BLA planned Q1 2027 after CMC package completion [Lilly 2026-07-23; Lilly 2026-09-29] |
| Filing ≠ approval | Submission timing is sponsor guidance; regulators decide |
SaiyanMed RUO framing: A planned BLA does not convert grey-market or research-chemical material into an approved drug. Laboratory reference materials remain Research Use Only.
Analytical / research identity (RUO)
Why a vial label is not clinical identity
“Retatrutide,” “LY3437943,” “Reta,” or “SM-301” on a lyophilized powder do not prove equivalence to Lilly’s clinical-trial drug product. Triple-agonist peptides can fail by wrong sequence/length, incomplete modification, isomer content, aggregation, residual solvents, or simple mislabeling. Cake appearance is not an analytical method.
Public product/education language on SaiyanMed describes a 39-amino-acid synthetic triple GIP/GLP-1/glucagon agonist reference material for laboratory study [Product page]. Treat sequence length and mass as claims to verify on the lot COA, not as automatic proof of clinical-grade identity.
Minimum COA packet (research buyer checklist)
| Item | Why it matters |
|---|---|
| Lot-matched COA | Must match the vial lot — not a “representative” PDF |
| RP-HPLC / UPLC purity + chromatogram | Area-% under a stated method; inspect shoulders |
| Intact-mass LC-MS | Observed vs theoretical mass for the intact modified peptide |
| Peptide content / counterion / water | Separates peptide mass from salt and residual solvent |
| Third-party testing when available | Reduces conflict of interest vs in-house-only sheets (SaiyanMed product page emphasizes Janoshik COA for listed lots) |
| Traceability | Manufacture/test dates, method IDs, lab identity |
For complex modified peptides, HPLC area-% without mass identity is incomplete — same quality philosophy as other SaiyanMed peptide hubs.
Handling themes (no recipes)
Lyophilized peptides are commonly stressed by moisture, heat, light, and repeated freeze–thaw after reconstitution. Follow the batch COA and your institution’s validated procedures. This article does not provide diluent volumes, concentrations, injection instructions, titration schedules, or study protocols.
Soft link to SaiyanMed RUO product
Qualified laboratories that need a documented research reference material can review the existing catalog listing: Retatrutide (RUO) product page — research use only; not for human or veterinary administration; not a substitute for any approved medicine; not Lilly clinical-trial supply.
Related SaiyanMed pages
| Page | Role vs this hub |
|---|---|
| What Is Retatrutide (this draft) | Pillar identity + Phase 3 evidence map |
| Product: Retatrutide RUO | Catalog / COA soft-link only |
| Retatrutide receptor pharmacology / GIPR structural basis | Deep MoA; do not duplicate here |
| Eloralintide vs Retatrutide | Amylin mono vs triple incretin compare |
| Retatrutide + MOTS-c stack evidence map | Evidence-map only — PubMed combo gap / identity checks; not a stacking protocol |
| What Is Eloralintide | Amylin-class neighbor |
| What Is Petrelintide | Amylin-class neighbor |
| Tirzepatide vs Semaglutide | Dual vs mono context |
Cannibalization rule: Keep deep receptor structure on the existing MoA URL; keep MOTS-c pairing skepticism on the evidence-map URL; this hub owns “what is + TRIUMPH/TRANSCEND map.”
Myth vs evidence
| Myth | Evidence-based correction |
|---|---|
| “Retatrutide is already an approved fat-loss drug.” | Still investigational; Lilly plans BLA Q1 2027; not approved [Lilly 2026-07-23]. |
| “Research vials are the same as Lilly clinical supply / legal to sell for patients.” | Lilly: cannot be legally sold or marketed for human use; consumer sale claims are unlawful [Lilly 2026-10-28]. RUO ≠ approved drug. |
| “Triple agonist = tirzepatide with a new name.” | Tirzepatide is dual GIP/GLP-1; retatrutide adds glucagon-receptor agonism in sponsor framing [Lilly 2026-09-29]. |
| “−20.8% means every person / every dose / open-label folklore.” | TRIUMPH-2 12 mg efficacy-estimand mean at 80 weeks in T2D+obesity vs placebo −4.0%; dose- and population-specific [Lilly 2026-09-29]. |
| “TRANSCEND proves superiority forever vs all GLP-1s.” | Open-label H2H vs semaglutide 2 mg at 80 weeks; detailed paper pending; not a universal ranking [Lilly 2026-10-28]. |
| “MACE HR 0.82 in TRIUMPH-3 proves CV benefit.” | Exploratory; CI crosses 1.0; not a dedicated CVOT claim [Lilly 2026-07-23]. |
| “Stack with MOTS-c because forums say so.” | See evidence map — mechanism folklore ≠ co-administered evidence base. |
Glossary
- Triple agonist / triple RA: One peptide engaging GIPR, GLP-1R, and GCGR (Lilly framing for retatrutide).
- LY3437943: Eli Lilly development code for retatrutide.
- TRIUMPH: Phase 3 obesity/complication program umbrella.
- TRANSCEND-T2D: Phase 3 type 2 diabetes program; TRANSCEND-T2D-2 = H2H vs semaglutide 2 mg.
- Efficacy estimand: Lilly’s stated analysis assuming continued study intervention without prohibited rescue (see IR endnotes).
- BLA: Biologics License Application (U.S. filing pathway Lilly cites for retatrutide).
- RUO: Research Use Only — not for human or veterinary administration.
- COA: Certificate of Analysis for a specific lot.
FAQ
What is retatrutide?
Retatrutide (LY3437943) is an investigational once-weekly peptide triple agonist of GIP, GLP-1, and glucagon receptors developed by Eli Lilly. It is studied in Phase 3 obesity and type 2 diabetes programs and is not an approved medicine [Lilly 2026-09-29].
What is LY3437943?
LY3437943 is the Lilly development code for retatrutide; it appears on ClinicalTrials.gov titles (e.g., TRIUMPH-2) [NCT05929079].
Is retatrutide FDA-approved?
No. Lilly describes it as investigational and plans a BLA in Q1 2027 [Lilly 2026-07-23].
How does retatrutide differ from tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Retatrutide is framed as a triple agonist that also activates the glucagon receptor [Lilly 2026-09-29]. Mechanism difference ≠ a patient recommendation.
How does it differ from semaglutide?
Semaglutide is a mono GLP-1 receptor agonist. TRANSCEND-T2D-2 is an open-label Phase 3 head-to-head of retatrutide vs injectable semaglutide 2 mg in T2D [Lilly 2026-10-28].
What is the TRIUMPH program?
TRIUMPH is Lilly’s Phase 3 obesity/related-complications program for retatrutide (>5,800 participants across initial registrational trials per Lilly) [Lilly 2026-09-29]. TRIUMPH-2 (NCT05929079) studied T2D + obesity/overweight over 80 weeks.
What did TRIUMPH-2 show?
At 80 weeks (efficacy estimand), retatrutide 12 mg averaged −20.8% body weight vs −4.0% placebo, with A1C reductions around −1.5 to −1.6 %-points at higher doses (baseline A1C 7.7%) [Lilly 2026-09-29].
What is TRANSCEND-T2D-2?
A Phase 3 open-label trial (NCT06260722) comparing weekly retatrutide 9 mg and 12 mg with weekly semaglutide 2 mg in adults with T2D on metformin ± SGLT2i [Lilly 2026-10-28; NCT06260722].
Can research suppliers legally sell retatrutide for human use?
Lilly states the molecule cannot be legally sold or marketed for human use and that selling it to consumers is unlawful [Lilly 2026-10-28]. SaiyanMed’s listing is RUO laboratory reference material only.
Does SaiyanMed sell retatrutide?
Yes as a Research Use Only catalog item for qualified lab use — see product page. It is not for human/veterinary use and is not Lilly clinical-trial drug product.
Can I use these trial percentages as a personal protocol?
No. Trial figures are published research data under specific protocols. This page provides no dosing, reconstitution, or titration guidance.
Where is the deep receptor MoA discussion?
Retatrutide receptor pharmacology and structural basis of GIPR.
Key takeaways
- Retatrutide (LY3437943) is Lilly’s investigational GIP/GLP-1/glucagon triple agonist peptide — not approved; BLA planned Q1 2027 per Lilly.
- TRIUMPH-2 (NCT05929079): in T2D + obesity/overweight, 12 mg averaged −20.8% weight at 80 weeks vs −4.0% placebo (efficacy estimand) [Lilly 2026-09-29].
- TRIUMPH-3: severe obesity + CVD, up to −22.6% weight at 80 weeks; MACE analyses exploratory [Lilly 2026-07-23].
- TRANSCEND-T2D-2: open-label H2H vs semaglutide 2 mg — A1C −2.2% vs −1.8%; weight −20.9% (12 mg) vs −9.4% [Lilly 2026-10-28].
- This page is RUO education; soft-link product only with research-use language; deep MoA lives on the receptor pharmacology URL.
Related reading & research inquiry
- Retatrutide RUO product
- Retatrutide receptor pharmacology / GIPR
- Eloralintide vs Retatrutide
- Retatrutide + MOTS-c stack evidence map
- What Is Eloralintide · What Is Petrelintide
CTA (RUO soft): Laboratories needing lot-documented triple-agonist reference material can review the Retatrutide RUO product page and COA packet. Contact research support for lot questions — not for personal use, reconstitution coaching, or treatment advice.
Research Use Only disclaimer
Research Use Only. Content summarizes published molecular, clinical-development, and analytical-quality information for laboratory professionals. It does not provide medical or veterinary advice, validated experimental protocols, dosing or reconstitution instructions, or authorization for in-vivo work. Animal research requires applicable institutional approvals. Retatrutide remains investigational as a therapeutic candidate. SaiyanMed research materials are not for human or veterinary administration.
Sources & further reading
- Lilly IR — TRIUMPH-2 detailed / EASD (2026-09-29) — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-substantial-weight
- Lilly IR — TRIUMPH-2 + TRIUMPH-3 toplines / BLA Q1 2027 (2026-07-23) — https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional
- Lilly IR — TRANSCEND-T2D-2 vs Ozempic 2 mg (2026-10-28) — https://investor.lilly.com/news-releases/news-release-details/lillys-retatrutide-delivered-greater-a1c-reduction-and-more
- ClinicalTrials.gov NCT05929079 (TRIUMPH-2) — https://clinicaltrials.gov/study/NCT05929079
- ClinicalTrials.gov NCT05882045 (TRIUMPH-3) — https://clinicaltrials.gov/study/NCT05882045
- ClinicalTrials.gov NCT06260722 (TRANSCEND-T2D-2) — https://clinicaltrials.gov/study/NCT06260722
- SaiyanMed — product/retatrutide · receptor pharmacology · eloralintide vs retatrutide · MOTS-c evidence map · what-is-eloralintide · what-is-petrelintide · tirzepatide vs semaglutide